Mechanism of Eclipta prostrata L-Ligustrum lucidum Ait in the treatment of periodontitis.
10.7518/hxkq.2025.2025049
- Author:
Mengru GUO
1
;
Tianyi ZHANG
2
;
Jingwen HUANG
2
;
Xinyue HUANG
1
;
Yi ZHENG
2
;
Li ZHANG
1
Author Information
1. Dept. of Emergency, Hospital of Stomatology, Jilin University, Changchun 130021, China.
2. Dept. of Periodontics, Hospital of Stomatology, Jilin University, Changchun 130021, China.
- Publication Type:Journal Article
- Keywords:
Eclipta prostrata L;
Ligustrum lucidum Ait;
inflammatory factors;
macrophage;
molecular docking;
network pharmacology;
oxidative stress;
periodontitis
- MeSH:
Periodontitis/drug therapy*;
Molecular Docking Simulation;
Eclipta/chemistry*;
Humans;
Protein Interaction Maps;
Ligustrum/chemistry*;
Antioxidants/pharmacology*;
Drugs, Chinese Herbal/therapeutic use*;
Network Pharmacology
- From:
West China Journal of Stomatology
2025;43(5):696-710
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:This study aimed to explore the potential target and molecular mechanism of Eclipta prostrata L-Ligustrum Lucidum Ait (EPL-LLA) in the treatment of periodontitis by using network pharmacology and molecular docking technology, and to explore its biocompatibility, regulatory effects on inflammatory factors, and antioxidant acti-vity through in vitro experiments.
METHODS:The active components and potential targets of EPL-LLA were screened and predicted through a variety of databases, and the intersection of EPL-LLA and periodontitis targets was selected. The protein interaction network (PPI) was analyzed by the string platform. The Metascape database was used for gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis. The active ingredients from the top 6 degrees were docked with the core targets, and the results of binding energy were visualized. An in vitro cell model was established to evaluate the biocompatibility, modulation of inflammatory factors, and antioxidative effects of EPL-LLA through cell counting kit-8 (CCK-8), quantitative real-time polymerase chain reaction (qRT-PCR) and 2',7'-Dichlorodihydrofluorescein diacetate (DCFH-DA) fluorescent probe assays.
RESULTS:Screening revealed 13 active components in EPL corresponding to 220 potential targets, 10 active components in LLA corresponding to 283 potential targets, and 1 643 periodontitis-related targets, with 91 shared targets among the three. GO analysis of the shared targets yielded 5 271 entries, while KEGG enrichment analysis indicated involvement in 253 signaling pathways. Molecular docking confirmed stable binding between the top 6 active components and core targets. CCK-8 assays demonstrated good biocompatibility of EPL-LLA at concentrations 0.02 mg/mL (P<0.05). qRT-PCR showed that EPL-LLA reduced the mRNA expression of pro-inflammatory factors in macrophages stimulated by Porphyromonas gingivalis lipopolysaccharide while upregulating anti-inflammatory factor mRNA expression (P<0.05). DCFH-DA fluorescence probe assays confirmed the reactive oxygen species (ROS)-scavenging capacity of EPL-LLA (P<0.05).
CONCLUSIONS:EPL-LLA may treat periodontitis through multi-component, multi-target, and multi-pathway mechanisms, providing a theoretical basis for further research on its therapeutic potential.
